- Home
- HBB vs CMPX Comparison
HBB vs CMPX Comparison
Compare HBB & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBB
- CMPX
- Stock Information
- Founded
- HBB 1904
- CMPX 2014
- Country
- HBB United States
- CMPX United States
- Employees
- HBB N/A
- CMPX N/A
- Industry
- HBB Home Furnishings
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- HBB Consumer Discretionary
- CMPX Health Care
- Exchange
- HBB Nasdaq
- CMPX Nasdaq
- Market Cap
- HBB 230.7M
- CMPX 214.6M
- IPO Year
- HBB 2017
- CMPX N/A
- Fundamental
- Price
- HBB $16.47
- CMPX $3.06
- Analyst Decision
- HBB
- CMPX Strong Buy
- Analyst Count
- HBB 0
- CMPX 4
- Target Price
- HBB N/A
- CMPX $13.75
- AVG Volume (30 Days)
- HBB 38.1K
- CMPX 2.8M
- Earning Date
- HBB 03-05-2025
- CMPX 03-20-2025
- Dividend Yield
- HBB 2.79%
- CMPX N/A
- EPS Growth
- HBB 107.04
- CMPX N/A
- EPS
- HBB 1.88
- CMPX N/A
- Revenue
- HBB $647,834,000.00
- CMPX $850,000.00
- Revenue This Year
- HBB $4.60
- CMPX N/A
- Revenue Next Year
- HBB N/A
- CMPX $613.39
- P/E Ratio
- HBB $8.63
- CMPX N/A
- Revenue Growth
- HBB 5.30
- CMPX N/A
- 52 Week Low
- HBB $14.34
- CMPX $0.77
- 52 Week High
- HBB $31.78
- CMPX $3.63
- Technical
- Relative Strength Index (RSI)
- HBB 36.77
- CMPX 65.64
- Support Level
- HBB $17.23
- CMPX $2.87
- Resistance Level
- HBB $18.11
- CMPX $3.29
- Average True Range (ATR)
- HBB 0.72
- CMPX 0.35
- MACD
- HBB 0.04
- CMPX 0.05
- Stochastic Oscillator
- HBB 24.00
- CMPX 68.93
About HBB Hamilton Beach Brands Holding Company
Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.